Women should have access to the medicines they need to live their best and fullest lives. Medicines360 is helping in a unique way.


Latest Updates

Press Releases

Medicines360 Appoints Tina Raine-Bennett, MD, MPH, FACOG, as Chief Executive Officer

Dr. Raine-Bennett brings passionate expertise in improving health outcomes for women SAN FRANCISCO – July 6, 2021 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett, MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search. With over 30 years of experience, Dr. Raine-Bennett has an extensive […]

Read More >
Press Releases

Medicines360 Applauds Introduction of Federal Legislation to Support Nonprofit Pharmaceutical Organizations

For Immediate Release: June 25, 2021 SAN FRANCISCO – Today, Senator Jacky Rosen (D-NV) introduced the Expanding Access to Affordable Prescription Drugs and Medical Devices Act, a bill designed to support nonprofit pharmaceutical organizations in their efforts to sustainably increase access to affordable medicines for Americans. As the longest-standing nonprofit pharmaceutical organization serving the U.S. market, […]

Read More >
Press Releases

Medicines360 and HRA Partner to Enhance Availability of Emergency Contraceptive ella® in the U.S.

SAN FRANCISCO and MORRISTOWN, N.J.: Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, and HRA Pharma, a global consumer healthcare company, announced today that the two organizations are partnering to support U.S. publicly funded family planning clinics’ access to prescription emergency contraceptive ulipristal acetate (UPA), commonly known in the U.S. as ella®. HRA Pharma first […]

Read More >
more updates

how we work

We’re reinventing the pharma business model: we identify areas in women’s health where patients face limited choices, develop medicines that expand women’s options and make them available in ways that close gaps in access.


We believe women should have access to medicines, regardless of their diverse needs. As we choose products for development and study them in robust clinical trials, we tackle areas where many women struggle with limited medicine choices.